CD274 and breast cancer: SG in combination with atezolizumab is being compared to the IMPassion030 regimen of nab-paclitaxel + atezolizumab in the front line for PD-L1+ a/m TNBC in the MORPHEUS-pan BC trial, with preliminary data showing an encouraging ORR of 76.7% versus 66.7% and immature PFS data of 12.2 months versus 5.9 months (HR 0.27) [7].